Tuberous sclerosis (TS) is caused by loss-of-function mutations of the TSC1 or TSC2 gene.
1 TSC1 and TSC2, respectively, encode hamartin and tuberin, which combine to suppress the mammalian target of rapamycin (mTOR) signaling pathway. 2, 3 The mTOR signaling pathway regulates cell proliferation and vascularization. 4 In patients with TS, the mTOR signaling pathway is abnormally activated due to diminished hamartin or tuberin function, leading to hamartomatous cell growth and other symptoms. 2, 3 Cardiac rhabdomyoma is one of the features of TS in the neonatal and early infantile periods. In half of rhabdomyoma cases, the rhabdomyomas spontaneously regress in childhood.
5
Everolimus is an mTOR inhibitor. Its effectiveness against subependymal giant cell astrocytomas, 3, 6 renal angiomyolipomas, 7 and epilepsy 8 in patients with TS has been documented.
There are some reports of cardiac rhabdomyoma treatment using everolimus, [9] [10] [11] [12] [13] [14] [15] [16] [17] but none describes the serious complications associated with its use. We report herein a neonate with TS and giant cardiac rhabdomyomas occupying the right ventricular cavity, impeding ventricular function, and decreasing pulmonary blood flow. Lipoprostaglandin E1 (lipo-PGE1) was required to maintain patency of the ductus arteriosus. Everolimus administration successfully reduced the tumor size although the clinical course was complicated by a pulmonary hemorrhage attributed to the adverse effects of everolimus.
tumors. Although the fetus had cardiac enlargement with a cardiac thoracic area ratio of 67% at 35 gestational weeks, the fetus developed neither arrhythmia nor hydrops. A male infant was born at 38 weeks' gestation by scheduled cesarean section due to a previous cesarean section. The birth weight was 2,029 g, the heart rate was 138 beats per minute, the respiratory rate was 20 breaths per minute, the blood pressure was 60/37 mm Hg, and oxygen saturation was 90% without any respiratory support at neonatal intensive care unit admission. A systolic heart murmur (grade 4/6) and peripheral coldness were found. There was no skin lesion, and the blood test showed no abnormalities.
The largest intracardiac tumor, 35 mm Â 21 mm in size, occupied the right ventricular cavity (►Fig. 1a), resulting in decreased right ventricular output. Echocardiography showed scant antegrade blood flow via the pulmonary valve and significant pulmonary regurgitation caused by backward blood flow from the ductus arteriosus. The right atrium was dilated, and a right-to-left shunt through the foramen ovale was detected. Stenosis of the left ventricular outflow tract due to the tumor was observed, and the flow velocity of the ascending aorta increased (1.5 m/s), but the systemic blood pressure remained normal. Since the pulmonary blood flow was dependent on the ductus arteriosus, we started lipo-PGE1 (5 ng/kg/min) soon after birth to maintain patency of the ductus arteriosus.
A magnetic resonance imaging of the brain showed cerebral white matter radial migration lines, a cortical tuber, and a subependymal nodule. Multiple retinal nodular hamartomas were also observed. TS was diagnosed based on these three major findings (brain, retina, and heart).
1
Volume reduction of the cardiac rhabdomyomas was crucial to maintain pulmonary blood flow. We decided to use everolimus to reduce the cardiac rhabdomyomas rapidly. We started once daily oral everolimus administration on day 4. The initial dosage of 0.4 mg/d (2.8 mg/m 2 /d, 0.2 mg/kg/d) was decided based on previous reports. 3, 18 The target trough level was set at 5 to 15 ng/mL. 6 Echocardiography at day 7 demonstrated a decrease in the tumor size in the right ventricle and an increase in the antegrade blood flow via the pulmonary valve. We terminated lipo-PGE1.
We experienced a serious complication at day 6, 3 days after the initiation of everolimus administration, when the patient's respiratory condition worsened and mechanical ventilation was started. Continuous bloody tracheal aspiration indicated a pulmonary hemorrhage, and the laboratory data revealed severe coagulopathy with a prothrombin time-international normalized ratio (PT-INR) of 2.4 and fibrinogen value of 52 mg/dL, as well as elevated liver enzymes. We decided to stop everolimus on day 7 after the fourth administration. After a single infusion of freshfrozen plasma, the coagulopathy improved (PT-INR 1.6 and fibrinogen 158 mg/dL) at day 9. Acne, which appeared on the bilateral cheeks at day 8, was treated with topical quinolone medication and improved after 2 weeks. Hyperlipidemia, hyperglycemia, and stomatitis were not observed.
Echocardiography at day 16 showed closure of the ductus arteriosus, confirming that biventricular circulation was achieved. The patient was weaned from mechanical ventilation on the same day.
With general improvement in the patient's condition, we tried to restart everolimus in the hope of further reducing the tumor size. At day 10, everolimus was administered at a lower dose of 0.1 mg/d. However, we discontinued everolimus again after we obtained the serum drug concentration measurement for day 7 showing a trough level of 76.1 ng/mL, which significantly exceeded the target level. At day 25, everolimus was administered at a dose of 0.025 mg/d, which resulted in a re-elevation of the liver enzymes. After everolimus was terminated altogether, the liver enzyme levels normalized again. Changes in the serum everolimus concentration and liver enzymes are shown in ►Fig. 2.
Echocardiography at days 20 (►Fig. 1b) and 42 (►Fig. 1c) showed regression of the giant tumor in the right ventricle. The patient was discharged at day 54.
Discussion
Everolimus was effective as a treatment of the giant cardiac rhabdomyomas with TS in our case; the drug reduced the tumor size rapidly, increased pulmonary blood flow, and 9-17 Cardiac rhabdomyomas with TS usually spontaneously regress in childhood.
5 Therapeutic intervention is not needed unless arrhythmia or severe intracardiac obstruction occurs. 19 In cases of refractory arrhythmia or severe obstruction of blood flow, surgery for tumor resection or single ventricular hemodynamics is necessary during the neonatal period. 20 Given the effectiveness of everolimus in rapidly reducing the size of rhabdomyomas, the drug may be a viable treatment option for giant cardiac rhabdomyomas in patients with TS. The appropriate dosage of everolimus has not been determined. Previous studies have set the everolimus target trough level at 5 to 15 ng/mL.
9,10,12-17 The package insert recommends monitoring the serum drug concentration from 2 weeks after commencing administration or changing the dosage. In our case, everolimus was administered at a dose of 0.2 mg/kg once daily starting at day 4. The serum everolimus concentration, measured immediately before the administration of the 4th dose at day 7, was 76.1 ng/mL, which was much higher than the target trough level. Our measurement of the serum drug concentration, which we made much earlier than recommended by the package insert, indicated that the initial dose should have been lower. Although the half-life of the drug is reportedly 25 to 43 hours, 21 the estimated half-life in our case was 84 to 128 hours, far exceeding the reported values. Our case underscores the fact that meticulous monitoring of the serum everolimus concentration is essential. Our patient developed pulmonary hemorrhage coinciding with the elevation of the serum everolimus concentration. Everolimus reportedly damages not only tumor vessels but also normal blood vessels 22 and can lead to pulmonary hemorrhage. 23 A recent in vivo study suggested that mTOR inhibitors may interact with the STAT1 gene, causing amplification of cellular apoptosis and augmenting lung injury. 24 Coagulopathy, which developed in our patient, is another possible complications. In the present case, in addition to increased pulmonary blood flow due to lipo-PGE1, tumor shrinkage caused by everolimus increased the pulmonary blood flow. All these factors contributed to the pulmonary hemorrhage. Everolimus can adversely affect liver function and lead to decreased metabolism of the drug. In our patient, an elevation of aspartate transaminase and alanine transaminase was evident at day 7 when the serum everolimus concentration peaked, and acne was also observed. As summarized in ►Table 1, complications reported in neonates include mouth ulcers, hyperlipidemia, etc. Liver dysfunction and acne were listed among the possible complications in the package insert in 2018, in which the incidence rates of liver dysfunction and acne were 1 to 10%. Half the Japanese population lack the activity of CYP3A5, the enzyme involved in everolimus metabolism.
21,25 Although we did not assess enzyme activity in our patient, the extremely high concentration of everolimus and the prolongation of its half-life might be related to the lack of CYP3A5 activity. The toxic and therapeutic levels of the serum everolimus concentration also require clarification. Complications, such as mouth ulcer and hyperlipidemia, have been documented in patients with concentrations of everolimus below the target trough level of 5 to 15 ng/mL. 9, 11, 15 In contrast, there were no complications in a case reported by Shigemitsu et al 13 despite a maximum trough level of 21 ng/mL.
Follow-up after the cessation of everolimus treatment is also important. Some studies reported tumor regrowth after stopping everolimus administration. 11, 12 It is also necessary to follow the long-term growth and development of pediatric patients who have received everolimus. There are as yet no reports on the long-term prognosis of neonates or young children who have received this treatment.
26
In conclusion, everolimus may be a viable treatment option for giant cardiac rhabdomyomas in patients with TS. When administering the drug to neonates, the patient should be closely observed for possible side effects, and the serum drug level should be routinely monitored. Ethical Approval All the procedures involving human participants were performed in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments. The approval of the ethics review committee and parental consent to use everolimus were obtained. Parental written informed consent was obtained for this report.
Funding
No financial assistance was received to support this study.
Conflict of Interest
All the authors declare that they have no conflict of interest.
